Ameni Bedoui

Dr. Ameni Bedoui


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2026 in Biology
Verified
Journal Article
Open access
PDF file
Mohamed JEMAAMohamed JEMAA
Mohamed JEMAA
ABAmeni Bedoui
Ameni Bedoui
NANihel Ammous
Nihel Ammous
AGAli Faouzi Gargouri
Ali Faouzi Gargouri
MGMohamed Guerfali
Mohamed Guerfali
Whole-genome duplication, or tetraploidization, occurs in cells, tissues, or entire organisms. In human cancers, tetraploidization promotes aneuploidy and genomic instability, accelerating tumor progression, metastasis, and drug resistance. These adaptations demand metabolic rewiring, including mitochondrial plasticity. Here, we investigate the relationship between mitochondrial quantity/activity, including the mitochondrial transmembrane potential, the intracellular calcium, and the oxidative stress in diploid versus tetraploid cancer cells (colon, sarcoma, liver) and fungal and yeast models (C. albicans diploid/tetraploid strains; S. cerevisiae haploid/diploid/tetraploid strains). We demonstrate that tetraploid cells, whether from human carcinomas or yeast, exhibit consistently enlarged cell size, elevated mitochondrial content, and heightened metabolic activity compared to diploids. Our findings underscore mitochondrial adaptation as a hallmark of tetraploidization, offering novel therapeutic targets for chromosomally unstable tumors.

24 July 2026 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
NLNour Louati
Nour Louati
IFImen Frikha
Imen Frikha
IDIkram Dammak
Ikram Dammak
IKImen Krichen
Imen Krichen
ABAmeni Bedoui
Ameni Bedoui
IAIkram Ben Amor
Ikram Ben Amor

3 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAmeni Bedoui
Ameni Bedoui
WAWajdi Ayadi
Wajdi Ayadi
NLNour Louati
Nour Louati
IFImen Frikha
Imen Frikha
YFYosra Fakhfakh
Yosra Fakhfakh
RGRaja Mokdad Gargouri
Raja Mokdad Gargouri
Acute lymphoblastic leukemia (ALL) is a heterogeneous malignancy characterized by various genomic alterations playing a crucial role in disease classification, prognosis, and response to treatment. However, molecular diagnosis and effective management of this hematological malignancy remain a major challenge, particularly in developing countries, including Tunisia. In this study, we aimed to conduct a detailed analysis of copy number alterations (CNAs) associated with ALL in a cohort of 60 primary samples from Tunisian patients. Using multiplex ligation-dependent probe amplification (MLPA), major genetic lesions, including IKZF1 , CDKN2A/2B , PAX5 , ETV6 , BTG1, and genes located in the PAR1 region, were analyzed and their associations with clinical and laboratory features, as well as survival outcomes, were also evaluated. Our analysis revealed that 70% of patients had deletions and/or amplifications in at least one gene. The most frequently observed deletions were in CDKN2A/2B (33.3%, n = 20), IKZF1 (30%, n = 18), and PAX5 genes (25%, n = 15). BTG1 deletions were significantly associated with female gender, IKZF1 deletions were more frequent in adult patients, in those with elevated white blood cell (WBC) counts, and in cases involving the BCR::ABL1 translocation, while duplications of the PAR1 region were significantly associated with hyperdiploïdy. Regarding treatment response, cases of IKZF1 deletions showed a significant association with poor glucocorticoid response (GC) at day 8 of treatment and positive minimal residual disease (MRD) rates at days 33 and 63, particularly in B-ALL cases. Furthermore, patients with IKZF1 deletions were associated with significantly lower survival rates in both univariate and multivariate analyses compared to those without these deletions. Additionally, the integration of IKZF1 deletion status into risk stratification models revealed markedly different survival outcomes, highlighting its potential interest in developing new stratification algorithms. These results underscore the critical importance of molecular profiling, particularly IKZF1 status, for improving outcomes in ALL patients in Tunisia.